NeuroSense Therapeutics (NRSNW) Stock Analysis

What NeuroSense Therapeutics does

NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.

Key metrics

ETFs linked to NRSNW

Broad-market and Healthcare sector ETFs an investor holding NeuroSense Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NRSNW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NeuroSense Therapeutics?

NeuroSense Therapeutics trades under the ticker NRSNW on NASDAQ.

Which exchange is NRSNW listed on?

NRSNW is listed on NASDAQ.

What sector does NeuroSense Therapeutics operate in?

NeuroSense Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NRSNW in a portfolio?

PortView shows NRSNW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.